SCHEMBL5143009

SCHEMBL5143009

Nc1c[nH]c(=O)nc1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27533747 0.76
SCHEMBL65897 0.76
SCHEMBL65486 0.76
SCHEMBL1765946 0.76
Flucytosine SCHEMBL24063 0.76
SCHEMBL30609151 0.76
SCHEMBL1231792 0.76 ATAD2 (0.37)
SCHEMBL22008 0.76
Flucytosine SCHEMBL8160959 0.76 ALDH1A1 (0.37)
SCHEMBL10910615 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108727402-B Oxaspiro bridged ureidopyrimidone compound and synthetic method thereof 常州大学 2020-09-08 CN claimed
EP-0898575-B1 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KOESTER HUBERT DR (US) 2004-12-29 EP claimed
US-20030194741-A1 COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES CAPROTEC BIOANALYTICS GMBH (DE) 2003-10-16 US claimed
US-20030054410-A1 Combinatorial protecting group strategy for multifunctional molecules CAPROTEC BIOANALYTICS GMBH (DE) 2003-03-20 US claimed
EP-0898575-A2 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KÖSTER, Hubert (US) 1999-03-03 EP claimed
WO-1997041139-A2 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KOESTER HUBERT (US) 1997-11-06 WO claimed
JP-1113389-A None JP disclosed
US-20250388903-A1 Methods and Compositions for Adar-Mediated Editing KORRO BIO INC (US) 2025-12-25 US disclosed
US-20250382610-A1 RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF KORRO BIO INC (US) 2025-12-18 US disclosed
US-20250352667-A1 METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING KORRO BIO INC (US) 2025-11-20 US disclosed
US-12448620-B2 RNA-editing oligonucleotides and uses thereof KORRO BIO, INC. (US) 2025-10-21 US disclosed
US-20250215038-A1 RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF KORRO BIO, INC. 2025-07-03 US disclosed
US-20250066773-A1 RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF KORRO BIO, INC. 2025-02-27 US disclosed
US-4879377-A Nucleoside process BRISTOL-MYERS COMPANY (US) 1989-11-07 US disclosed
WO-1989005649-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES BRIGHAM YOUNG UNIVERSITY (US) 1989-06-29 WO disclosed
JP-H01113389-A PREPARATION OF FUSED PYRIDINE COMPOUND UNIV PRINCETON 1989-05-02 JP disclosed
EP-0145978-B1 NUCLEOSIDE PROCESS Bristol-Myers Company (US) 1989-04-19 EP disclosed
US-4625020-A Nucleoside process BRISTOL-MYERS COMPANY (US) 1986-11-25 US disclosed
EP-0145978-A2 Nucleoside process Bristol-Myers Company (US) 1985-06-26 EP disclosed
US-3935184-A Synthetic polyoxin type nucleosides SYNTEX (U.S.A.) INC. (US) 1976-01-27 US disclosed